etomoxir has been researched along with Heart Failure in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (76.47) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Arduini, A; Ceccarelli, SM; Chomienne, O; Gubler, M | 1 |
| Aksentijević, D; Shattock, MJ | 1 |
| Heggermont, WA; Heymans, S; Papageorgiou, AP; van Bilsen, M | 1 |
| Di Napoli, P | 1 |
| Blum, D; Doenst, T; Faerber, G; Mohr, FW; Pytel, G; Rueckauer, T; Schwarzer, M | 1 |
| Mellana, WM; Mohan, D; Palaniswamy, C; Selvaraj, DR | 1 |
| Maisch, B; Rupp, H; Zarain-Herzberg, A | 1 |
| Taegtmeyer, H | 1 |
| Maisch, B; Rupp, H; Rupp, TP | 2 |
| Rupp, H | 1 |
| Boehm, E; Holubarsch, CJ; Karrasch, M; Polonski, L; Ponikowski, P; Rhein, S; Rohrbach, M | 1 |
| Holubarsch, C; Schmidt-Schweda, S | 1 |
| Bristow, M | 1 |
| Rupp, H; Vetter, R | 1 |
| Rupp, H; Zarain-Herzberg, A | 1 |
| Maisch, B; Rupp, H | 1 |
7 review(s) available for etomoxir and Heart Failure
| Article | Year |
|---|---|
With a grain of salt: Sodium elevation and metabolic remodelling in heart failure.
Topics: Animals; Epoxy Compounds; Heart Failure; Humans; Myocardium; Sodium | 2021 |
Metabolic support for the heart: complementary therapy for heart failure?
Topics: Acetyl-CoA C-Acyltransferase; Cardiovascular Agents; Carnitine; Carnitine O-Palmitoyltransferase; Dichloroacetic Acid; Energy Metabolism; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Glucose; Heart Failure; Humans; Myocardium; Myocytes, Cardiac; Oxidation-Reduction; Perhexiline; Ranolazine; Stroke Volume; Trimetazidine | 2016 |
Metabolic modulation: a new therapeutic target in treatment of heart failure.
Topics: Acetanilides; Carnitine O-Palmitoyltransferase; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Glucose; Heart Failure; Humans; Mitochondria, Heart; Myocytes, Cardiac; Perhexiline; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents | 2011 |
The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Topics: Acetanilides; Angina Pectoris; Animals; Calcium; Cardiovascular Agents; Clinical Trials as Topic; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Gene Expression; Glucose; Heart Failure; Humans; Hypoglycemic Agents; Methylhydrazines; Myocytes, Cardiac; Oxidation-Reduction; Piperazines; Ranolazine; Rats; Rats, Wistar; Sarcoplasmic Reticulum; Trimetazidine; Up-Regulation; Vasodilator Agents | 2002 |
[Metabolism and the hypertrophied heart of the elderly].
Topics: Animals; Blood Glucose; Calcium-Transporting ATPases; Cardiomegaly; Carnitine O-Palmitoyltransferase; Energy Metabolism; Epoxy Compounds; Fatty Acids; Gene Expression Regulation; Heart Failure; Hemodynamics; Humans; Hypolipidemic Agents; Myocardial Contraction; Myocardium; Oxidation-Reduction; PPAR alpha; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2005 |
Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target.
Topics: Animals; Calcium-Transporting ATPases; Carnitine O-Palmitoyltransferase; Enzyme Inhibitors; Epoxy Compounds; Gene Expression Regulation, Enzymologic; Heart Failure; Humans; Mice; Molecular Sequence Data; Myocytes, Cardiac; Myosin Heavy Chains; Rabbits; Rats; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sequence Homology, Amino Acid; Transcriptional Activation | 2002 |
[Functional genomics of pressure-loaded cardiomyocytes: etomoxir in heart failure?].
Topics: Animals; Calcium-Transporting ATPases; Enzyme Inhibitors; Epoxy Compounds; Gene Expression Regulation; Heart Failure; Hemodynamics; Humans; Myocardium; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Ventricular Dysfunction, Left | 2002 |
2 trial(s) available for etomoxir and Heart Failure
| Article | Year |
|---|---|
A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) stud
Topics: Adult; Aged; Aged, 80 and over; Carnitine O-Palmitoyltransferase; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Epoxy Compounds; Exercise Test; Female; Heart Failure; Humans; Liver; Male; Middle Aged; Stroke Volume; Treatment Outcome; Ultrasonography | 2007 |
First clinical trial with etomoxir in patients with chronic congestive heart failure.
Topics: Adult; Aged; Enzyme Inhibitors; Epoxy Compounds; Exercise Test; Heart Failure; Heart Rate; Hemodynamics; Humans; Male; Middle Aged; Stroke Volume; Thermodilution | 2000 |
8 other study(ies) available for etomoxir and Heart Failure
| Article | Year |
|---|---|
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
Topics: Animals; Carnitine; Carnitine O-Palmitoyltransferase; Catalytic Domain; Diabetes Mellitus, Type 2; Energy Metabolism; Enzyme Activators; Ethylene Oxide; Heart Failure; Humans; Insulin Resistance; Isoenzymes; Lipid Metabolism; Myocardial Ischemia; Organ Specificity; Protein Conformation; Sequence Homology, Amino Acid; Stereoisomerism | 2011 |
The metabolic treatment of coronary artery disease and heart failure.
Topics: Carnitine O-Palmitoyltransferase; Coronary Artery Disease; Epoxy Compounds; Heart Failure; Humans; Perhexiline; Trimetazidine; Vasodilator Agents | 2009 |
The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo.
Topics: Animals; Cardiomegaly; Carnitine O-Palmitoyltransferase; Disease Models, Animal; Energy Metabolism; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Glucose; Heart Failure; Hypertension; Male; Myocardial Contraction; Myocardium; Myosin Heavy Chains; Oxidation-Reduction; Piperazines; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Rats; Rats, Sprague-Dawley; Stroke Volume | 2009 |
Cardiac metabolism as a target for the treatment of heart failure.
Topics: Acetanilides; Animals; Dogs; Energy Metabolism; Epoxy Compounds; Fatty Acids; Forecasting; Glucagon; Glucagon-Like Peptide 1; Glucose; Heart Failure; Humans; Insulin Resistance; Myocardium; Peptide Fragments; Piperazines; Protein Precursors; Ranolazine; Recombinant Proteins | 2004 |
Fatty acid oxidation inhibition with PPARalpha activation (FOXIB/PPARalpha) for normalizing gene expression in heart failure?
Topics: Animals; Carnitine O-Palmitoyltransferase; Clinical Trials as Topic; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Gene Expression Regulation; Glycine; Heart Failure; Humans; Hypoglycemic Agents; Oxidation-Reduction; PPAR alpha | 2005 |
Drug development based on functional genomics of overloaded cardiomyocytes: a novel approach for preventing progression of heart failure.
Topics: Animals; Calcium-Transporting ATPases; Disease Progression; Drug Design; Epoxy Compounds; Heart Failure; Humans; Myocytes, Cardiac; Rats; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2004 |
Etomoxir: a new approach to treatment of chronic heart failure.
Topics: Animals; Carnitine O-Palmitoyltransferase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Epoxy Compounds; Heart Failure; Humans; Hypoglycemic Agents; Rats | 2000 |
Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure.
Topics: Animals; Aortic Valve Stenosis; Body Weight; Calcium; Calcium-Transporting ATPases; Carnitine O-Palmitoyltransferase; Disease Progression; Enzyme Inhibitors; Epoxy Compounds; Heart Failure; Heart Ventricles; Hypertrophy; Isoenzymes; Myosins; Organ Size; Rats; Rats, Wistar; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Time Factors | 2000 |